GlassScriptPhysician profile
Ann Clark Ghory
NPI 1194759118
$4,084.98
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,653 · 2020: $824 · 2021: $352 · 2022: $731 · 2023: $489 · 2024: $35.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446 · Education: $63.99 · Consulting Fee: $14.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $445.81 |
| Education | $63.99 |
| Consulting Fee | $14.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,022.21 | 2019-2023 | Fasenra |
| Genzyme Corporation | $582.92 | 2019-2024 | |
| Glaxosmithkline, LLC. | $560.33 | 2019-2023 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $473.76 | 2019-2022 | |
| Genentech USA, INC. | $316.91 | 2019-2022 | |
| Covis Pharma Gmbh | $161.90 | 2019-2022 | |
| Optinose US, INC. | $142.34 | 2019-2022 | |
| Pfizer INC. | $123.09 | 2019-2022 | |
| Csl Behring | $104.55 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.20 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $63.99 | 2023 | |
| Adma Biomanufacturing LLC | $56.49 | 2021-2023 | |
| Shire North American Group INC | $47.12 | 2019 | |
| Octapharma USA, INC. | $46.23 | 2021-2023 | Cutaquig |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.03 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $37.34 | 2019-2023 | Xembify |
| Jubilant Hollisterstier LLC | $37.04 | 2019-2023 | |
| Kaleo, INC. | $35.73 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $35.03 | 2019-2022 | |
| Amgen INC. | $31.19 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $30.87 | 2021 | |
| Bio Products Laboratory USA, INC. | $20.61 | 2019 | |
| Alk-Abello, INC | $19.10 | 2023 | Grastek, Odactra, Ragwitek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Ghory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.